ABSTRACT: VEGF is a specific mitogen and survival factor for endothelial cells and a key promoter of angiogenesis in physiological and pathological conditions. Nevertheless, VEGF tissue evaluation in cancer patients as a prognostic factor compared to the conventional histological and biological parameters is still controversial. In this case-control study, tissue VEGF was retrospectively determined by immunohistochemistry and related to T, N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 in 129 breast cancer patients. Seventy-four of these patients had developed distant metastases postoperatively. The remaining 55 patients had remained disease-free >10 years after surgery. In 17 (13%) of the 129 patients (six with distant metastases and eleven disease-free) tissue and plasma VEGF were concomitantly evaluated. In univariate analysis no significant differences in VEGF and tumor size were found between metastatic and disease-free patients, whereas there were sig- 
INTRODUCTION
VEGF is a specific mitogen and survival factor for endothelial cells and a key promoter of angiogenesis in physiological and pathophysiological conditions (1, 2) . VEGF acts primarily in a paracrine way and binds to receptors of the basal membranes of the endothelium. It is required for the normal development of embryonic vasculature, the cyclic growth of blood vessels in the female reproductive tract, and the formation of capillaries during wound repair. VEGF is also involved in abnormal angiogenesis, as seen in proliferative retinopathies, rheumatoid arthritis, psoriasis, and malignancies. It locally initiates permeabilization of blood vessels, extravasation of plasma proteins, invasion of stromal cells, and sprouting of new blood vessels that supply the tumor with oxygen and nutriments and facilitate metastasis (3, 4) . It is currently assumed that all tissues have the potential to produce this growth factor. Its synthesis is stimulated when cells become deficient in oxygen or glucose and during inflammatory reactions. Tumor cells tend to overexpress VEGF constitutively.
The human vascular endothelial growth factor (VEGF) gene consists of eight exons and seven introns. The molecular mechanisms of the increase in VEGF mRNA and VEGF protein production are not yet understood. Hormones reported to influence VEGF mRNA production include insulin, insulin-like growth factor-1, corticotropin, thyrotropin, and steroid hormones. At least five isoforms of the VEGF protein, composed of 121, 145, 165, 189 and 206 amino acids, respectively, can be translated because of alternative VEGF mRNA splicing (1, 3) . Glycosylation is essential for efficient secretion. VEGF 121 is a freely soluble protein that does not bind heparin. VEGF 165 , the predominant isoform, is a heparinbinding basic homodimer of 45 kDa that remains partly bound to the cell surface and the extracellular matrix. The other isoforms do not enter the circulation in significant amounts because they are either bound to the extracellular matrix (VEGF 145 ) or secreted sparingly (VEGF 189 and VEGF 206 ). VEGF binds with high affinity to two tyrosine kinase receptors, the fms-like kinase (Flt-1, VEGFR-1) and the kinase domain receptor (KDR, VEGFR-2), which are produced predominantly by endothelial cells. The production of Flt-1 and KDR increases in response to hypoxia, although this increase is smaller than that of VEGF. Binding of VEGF causes receptor dimerization and autophosphorylation for signaling. The antiapoptotic and mitotic functions of VEGF are mediated by KDR. VEGF 165 can also bind to neuropilin-type receptors, which may explain why VEGF 165 is a more potent mitogen than VEGF 121 (3) .
The role of angiogenesis in cancer biology was championed by Folkman (5) , who first postulated in 1971 that solid tumors would remain dormant at a size of only 2 to 3 mm 3 in the absence of neovascularization because tumor growth is inhibited by the lack of oxygen and nutrients. Subsequent research provided definite evidence that tumor growth is angiogenesis dependent (6) and that angiogenesis is implicated in the initial progression from a premalignant tumor to cancer (4), invasion of cancer cells into the circulation (7), and growth of dormant micrometastases into frank metastatic lesions (8) . Hence, angiogenesis is involved from the very first stage of cancer formation to the final stage of distant metastasis.
Over the last decade the clinical applications of research on angiogenesis have taken two main directions: the quantitation of angiogenesis for use in diagnosis and prognosis, and the inhibition of angiogenesis to halt tumor growth. There is more solid evidence that supports the evaluation of tumor angiogenesis for prognosis in cancer patients (9) . An indirect way to measure angiogenic activity in cancer is to evaluate the expression of angiogenic factors in tumor tissue or the quantity of angiogenic proteins secreted into blood fluids (10, 11) .
Quantitative tissue evaluation of VEGF in cancer patients as a prognostic factor compared to the conventional histological and other biological parameters is still controversial (12) (13) (14) (15) (16) (17) (18) . In breast cancer some studies (19) (20) (21) (22) reported that tissue VEGF expression correlates with axillary lymph node involvement and poor prognosis but others did not (16, 23) .
In the present study VEGF expression was retrospectively determined in primary breast cancer patients who postoperatively developed distant metastases and in others who did not for a prolonged period of time. The prognostic value was compared with that of the conventional histological parameters and other biological prognostic factors.
MATERIAL AND METHODS

Patients
The study cases were 74 patients who postoperatively, from September 1981 to September 2001, had developed distant metastases. The study controls were 55 patients operated on between June 1977 and March 1991, who were selected because they had remained disease free for at least 10 years. VEGF was retrospectively determined in the primary tumor tissue of all 129 breast cancer patients. The age range of the entire group was 25 to 78 years. The 74 metastatic patients, aged 25 to 78 years (mean 57 + 12.5), were followed up for 78 + 58 months (mean + standard deviation); 16 (22%) of them were premenopausal. The remaining 55 non-relapsed patients, aged 29 to 71 years (mean 53 + 10 years) were followed up for 197 + 37 months; 24 (44%) of them were premenopausal. In 17 (six with and eleven without distant metastases) of the 129 studied patients both tissue and circulating VEGF was determined.
Prognostic factors in primary cancer tissue
VEGF determination was retrospectively carried out on smears of the primary tumor stained for histology. Four to five-µm-thick serial sections were cut from trimmed blocks and sections were placed on Superfrost Plus glass slides. Histopathological tissue typing was confirmed by a pathologist and performed according to the WHO criteria. For all patients postoperative TNM staging was available. Formalin-fixed, paraffin-embedded sections were stained with hematoxylin and eosin. Sections were dewaxed in xylene and rinsed in decreasing grades of ethanol.
VEGF, ER, PgR, MIB-1, cyclin D1, p53 and c-erbB-2 immunohistochemistry
Immunohistochemistry (IHC) was done with the streptavidin-biotin-peroxidase complex method (S-ABC). The slides for p53, ER, PgR and VEGF-A analysis were put in plastic jars filled with citrate buffer (pH 7.3) and heated for 3 x 5 minutes in a microwave oven at 750 W. The slides for cyclin D1 were put in plastic jars filled with 1 mM EDTA buffer (pH 9.0) and heated for 32 minutes in an oven at 240 W. After microwave treatment the sections were left to cool to room temperature for about 20 minutes and washed with distilled water for 5 minutes. On the slides for c-erbB-2 analysis, immunohistochemistry was applied directly without further pretreatment.
The immunohistochemistry analyses were performed by an automated avidin-biotin complex method on a Ventana Nexes (Ventana Medical Systems, Tucson, AZ, USA). Staining was performed using the mouse monoclonal anti-ER antibody (clone 6-F11, Ventana Medical Systems, pre-diluted, 32 minutes' incubation at 42°C), the mouse monoclonal anti-PgR antibody (clone PGR-1A6, Ventana Medical Systems, pre-diluted, 32 minutes' incubation at 42°C), the mouse monoclonal antibody MIB-1 (Immunotech-DBA, 1:100 diluted, 32 minutes' incubation at 42°C), the mouse monoclonal antibody cyclin D1 (clone DCS-6, Ventana Medical Systems, pre-diluted, 32 minutes' incubation at 42°C), the mouse monoclonal anti-p53 antibody (clone Bp53-11, Ventana Medical Systems, pre-diluted, 32 minutes' incubation at 42°C), the mouse monoclonal anti-HER-2 antibody (clone TAB250, Zimed, Histo-Line Laboratories, 1:100 diluted, 32 minutes' incubation at 42°C), and the rabbit polyclonal anti-VEGF-A antibody (clone A-20, Santa Cruz Biotechnology, Santa Cruz, CA, 1:50). The polyclonal antibody VEGF (A-20) reacts with the 165, 189 and 121 amino acid splice variants of VEGF of human, mouse and rat origin and has no cross-reactivity with other VEGF-PDGF family members. VEGF expression was cytoplasmic in all cases. All these prognostic factors were semiquantitatively determined. VEGF staining was scored by intensity (negative or weak, moderate, strong) and by the proportion of positive cells (% of staining). A final score of <3 or >3 was attributed by taking into account both the intensity and the proportion of positive cells. Intensity was scored as 0 (negative), 1 (weak), 2 (moderate), 3 (strong) and the proportion of positive cells was scored as 0 (0%), 1 (1% to 25%), 2 (26% to 50%), 3 (>50%). The cutoff values of ER, PgR, MIB-1, cyclin D1, p53 and c-erbB-2 were >10%, >10%, >10%, >10%, >0% and >0%, respectively.
Statistical analysis
Univariate and multivariate analysis by logistic regression was performed in all 129 breast cancer patients. Tissue VEGF and other common prognostic indicators were included in the analysis (Tab. I and II). The sensitivity and specificity of the tissue prognostic indicators and In multivariate analysis in the N+ and N-subgroups only the indicators that proved to be significant in univariate analysis were taken into account (Tab. IV). Tumors with negative VEGF immunostaining (IS) were grouped together with tumors having weak VEGF IS and tumors with moderate VEGF IS were grouped with tumors with strong VEGF IS (Tab. I-IV).
In Table V three categories of VEGF IS (negative or weak, moderate and strong) were considered and a comparison by chi-square test between relapsed and non-relapsed patients was carried out. The unpaired t test was used to compare %IS within each category of VEGF IS.
Disease-free interval and overall survival curves from mastectomy and from the diagnosis of metastases were evaluated by the Cox regression model (24) . For diseasefree interval all 74 metastatic patients were considered, while for survival from the time of mastectomy and relapse six of them (8%) were excluded because at relapse they had received some form of non-conventional experimental treatment (Tab. VI).
A multivariate analysis by the Cox regression model was performed with the following prognostic indicators as variables: axillary lymph node involvement (with or without), estrogen and progesterone receptors (positive or negative), c-erbB-2 (>0% and 0%), p53 (>0% and 0%), MIB-1 (>10% and <10%), cyclin D1 (>10% and <10%), and VEGF IS. Tumor size was excluded as a variable because of the large number of missing cases: in 15 (20%) patients tumor size was undetermined (Tx) (Tab. VI). In the logistic and Cox regression models prognostic indicators were selected by backward selection. 
RESULTS
VEGF and other common prognostic indicators in primary cancer tissue
Difference between relapsed and non-relapsed patients
In univariate analysis no significant difference was found with regard to Tis-T1 and T2-T3-T4 tumors and tumors with negative or weak, moderate and strong VEGF IS, or tumors with a VEGF score >3. The number of N+, ER-, PgR-, c-erbB-2+, p53+, MIB-1+ and cyclin D1+ tumors was significantly higher (p ranging from <0.001 to <0.0001) in the 74 metastatic than in the 55 disease-free breast cancer patients. MIB-1 and cyclin D1 showed the highest odds ratios (16.4 and 5.8, respectively) (Tab. I). In multivariate analysis p53 and PgR lost their significance, while decreasing levels of significance (ranging from p=0.001 to p=0.012) were found for cyclin D1+, N+, MIB-1+, c-erbB-2+ ER-and M-S (moderate-strong) VEGF (Tab. II).
VEGF score and VEGF IS showed the highest sensitivity (91% and 86%) but the lowest specificity (13% and 27%). Conversely, MIB-1 and cyclin D1 showed the highest specificity (96% and 82%) but were among the indicators with lowest sensitivity (39% and 55%). Among all evaluated indicators, N showed both relatively high sensitivity and specificity (69% and 71%). However, the sensitivity and specificity of logistic regression were higher than those of N (90% and 72%) (Tab. III).
When the three categories of VEGF IS were taken into account (negative or weak, moderate and strong), no significant difference was observed between the 74 relapsed patients and the 55 long-term event-free survivors. Furthermore, in each category no significant difference was seen with regard to %IS (Tab. IV).
VEGF immunostaining in patients with (N+) and without (N-) axillary lymph node involvement Between relapsed and non-relapsed breast cancer patients, MIB-1+ and ER-were significant in both subgroups (p=0.031 and p=0.050 in N+ and p=0.022 and p=0.021 in N-patients, respectively). Cyclin D1+ and cerbB-2+ were significant in the N-subgroup (p=0.000 and p=0.001) but they did not reach significance in the N+ subgroup (p=0.096 and p=0.275). M-S VEGF IS was significant in the N+ (p=0.015) but not in the N-subset (p = 0.516) (Tab. V).
Relationship of VEGF and the other prognostic tissue indicators to disease-free interval and survival from mastectomy and from the diagnosis of metastases in the 74 relapsed patients
In the multivariate analysis with regard to diseasefree interval, axillary lymph node involvement (N+) and PgR-were the only significant independent unfavorable variables (p=0.003 and p=0.012, respectively), while the c-erbB-2 p value was close to significance. With regard to overall survival from mastectomy, N+ was the only significant independent unfavorable variable (p=0.001). 
Relationship between tissue VEGF IS and plasma VEGF level
In two of the six metastatic and in two of the eleven disease-free breast cancer patients in whom both tissue and circulating VEGF was determined, the tissue VEGF score was <3, while in the remaining four and nine patients it was >3. The mean plasma level of metastatic and disease-free patients with tumors scoring <3 and tumors scoring >3 are shown in Table VII .
DISCUSSION
Although many studies on VEGF have been reported in recent years, its role in breast cancer is still controversial. Whether VEGF determination in primary tissue and in the circulation is useful also compared with the other currently available indicators is the principal question to be answered. Most data from this study refer to the determination of VEGF and other common prognostic indicators in tissue of primary cancer.
In univariate analysis, VEGF score, VEGF IS and tumor size did not show any significant differences between relapsed and non-relapsed patients, whereas N, ER, PgR, cerbB-2, MIB-1, cyclin D1 and p53 did. In multivariate analysis, ER-, c-erbB-2+, MIB-1+, N+ and cyclin D1+ maintained their significance; M-S VEGF IS proved to be significant but was the weakest predictor of relapse. Moreover, only N and logistic regression showed a sufficiently high concomitant sensitivity and specificity. Also when the three categories of VEGF IS (negative or weak, moderate, strong) were taken into account, no significant difference was observed between relapsed patients and long-term event-free survivors. The conventional histological parameter (axillary lymph nodes) and other common biological factors (ER, c-erbB-2, MIB-1 and cyclin D1) were therefore more useful as prognostic indicators than VEGF.
Some reports recently showed an important unfavorable prognostic value of tissue VEGF in the subgroup of N-breast cancer patients (20, 21, 25) , while in studies on N+ subgroups this finding was more controversial (19, 23) . In both the 67 N+ and 62 N-patients of this study, MIB-1+ and ER-status showed a significant difference between relapsed and non-relapsed patients, while significance of M-S VEGF IS was found only in the 67 N+ patients. Therefore, in the N+ and N-subsets of this study, VEGF was less useful than MIB-1+ and ER-. Moreover, it also proved to be a less useful indicator than cyclin D1+ and c-erbB-2+, which were significant in the 62 N-but not in the 67 N+ patients. In fact, current guidelines consider N+ patients as having a poor prognosis and all N+ patients are given adjuvant treatment, whereas N-patients are not. Consequently, it is important for the clinical oncologist to correctly predict relapse in N-patients. Multivariate analysis by the Cox model showed that tissue VEGF IS, unlike N and PgR, was no significant variable for disease-free interval and overall survival from relapse and from mastectomy in the 74 relapsed patients. This means that also in relapsed patients tissue VEGF IS does not play a relevant role as an independent prognostic factor.
These findings agree with the literature data. As a matter of fact, tissue VEGF has been reported to be an independent unfavorable prognostic factor for relapse and survival in a few studies (19, 21, 26) . In some of these it was found to be an unfavorable prognostic factor in subsets such as N- (20, 21, 25) , N+ (19) or ER+ (27) patients. Only occasionally was it reported to be more helpful than the conventional histological parameters or the other common biological prognostic indicators. This is not easy to understand at first sight. Indeed, Folkman's hypothesis states that tumor growth is angiogenesis dependent, and that each increment of tumor growth requires an increment of capillary growth. This hypothesis was validated by hundreds of experiments. At the time of Folkman's hypothesis it was thought that tumor angiogenesis depended on a "tumor angiogenesis factor" produced by tumor cells. As VEGF is an important endogenous stimulator of angiogenesis, a relevant predictive and prognostic role of tissue VEGF would be expected. However, we know now that tumors overexpress many non-tumor-specific angiogenic growth factors and that angiogenesis is a tightly coordinated "balancing act". In fact, many oncogenes and tumor suppressor genes, growth factors and endogenous inhibitors, proteases and protease inhibitors and trace elements can switch angiogenesis "on" or "off".
The complexity of the mechanism of angiogenesis can explain the failure of the antiangiogenic therapies used to date. In most of them the target of treatment is the inhibition of a single angiogenic factor. For the same reason it is possible that no single angiogenic factor has a highly significant predictive and prognostic value. It is therefore not surprising that the prognostic and predictive value of tissue VEGF IS is lower than that of the conventional histological and other common biological indicators.
Finally, and consistent with the literature (28), in relapsed and non-relapsed patients in whom tissue VEGF IS and plasma VEGF level were determined, the mean plasma VEGF level in tumors with a tissue VEGF score >3 was similar to that in tumors with a tissue VEGF score <3.
In conclusion, tissue VEGF does not seem a suitable candidate to replace the conventional histological and other common biological prognostic factors in breast cancer.
